Outcome selection and role of patient reported outcomes in contemporary cardiovascular trials: systematic review
Open Access
- 1 November 2010
- Vol. 341 (nov01 1) , c5707
- https://doi.org/10.1136/bmj.c5707
Abstract
Objectives To systematically assess the type of outcomes selected and the prevalence of patient reported outcomes in contemporary cardiovascular trials and to quantify any misuse or underuse of patient reported outcomes using a specially developed tool that would allow estimation of the relevance of such outcomes to clinical decision making.Design Systematic review.Data sources Medline and Embase.Study selection Randomised controlled trials of the treatment for or prevention of cardiovascular disease published in 10 leading general medical and cardiology journals from January 2005 to December 2008.Results Primary outcomes were patient important (death, morbidity, or patient reported outcomes) in only 93 of 413 trials (23%, SE 2%), whereas another 92 (22%, SE 2%) combined these outcomes with other less important ones into a composite. Sixty five trials (16%; SE 2%) used at least one instrument to measure patient reported outcomes, mostly in trials where such information would have been important or crucial for clinical decision making (52 trials). Patient reported outcomes were judged to be of little incremental value to a large number of, mostly explanatory, cardiovascular trials (152 trials). However, many trials in which patient reported outcomes would have been important or crucial for clinical decision making did not report such outcomes (122 of 174 trials, 70%). These included several trials that primarily aimed to improve symptoms or functional status, trials that tested interventions with a considerable potential for causing harm (mainly bleeding) that were not meaningfully measured, and trials with composite outcomes that were dominated by outcomes of questionable importance to patients.Conclusions Despite a continued rise in the reporting of patient reported outcomes with no evidence for their misuse in more recent cardiovascular trials, they seem to be still underused once their relevance to clinical decision making has been taken into account. This was largely explained by inappropriate use of composite outcomes and inadequate measurement of harms.Keywords
This publication has 30 references indexed in Scilit:
- Weighing Benefits and Risks — The FDA's Review of PrasugrelNew England Journal of Medicine, 2009
- Patient-Important Outcomes in Registered Diabetes TrialsJAMA, 2008
- Effects of Citalopram and Interpersonal Psychotherapy on Depression in Patients With Coronary Artery DiseaseJAMA, 2007
- Quality of Life Assessment of Randomized Controlled TrialsTumori Journal, 2006
- Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom OnsetA Randomized Controlled TrialJAMA, 2005
- High-Dose Folic Acid Acutely Improves Coronary Vasodilator Function in Patients With Coronary Artery DiseaseJournal of the American College of Cardiology, 2005
- Losartan Increases Bradykinin Levels in Hypertensive HumansCirculation, 2005
- Quality-of-Life Assessment in Cancer Treatment Protocols: Research Issues in Protocol DevelopmentJNCI Journal of the National Cancer Institute, 1992
- Measuring quality of life in clinical trials: a taxonomy and review.1989
- Development and testing of a new measure of health status for clinical trials in heart failureJournal of General Internal Medicine, 1989